VIDEO: Secondary cancers found after stem cell transplants for multiple myeloma
In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
While Richardson notes that much of the side effect results were expected, the study produced some findings of concern, namely the secondary cancer signal and a transient drop of quality of life in transplant patients.
“While fortunately the numbers were low, we did see significantly more cases of [acute myeloid leukemia] and [myelodysplastic syndromes] with early transplant,” Richardson said.
- Richardson,P, et al. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.